Due to recent changes in the official account push mechanism, we welcome you to set Boom Health as a "starred" account on the homepage of the official account to get the latest trends and expert insights in the digital healthcare industry第一时间!
01 Global Digital Health Investment and Financing OverviewNuvig Therapeutics, a developer of transformative therapies for chronic inflammation and autoimmune diseases, secures $161 million in Series B financingOn December 5, Nuvig Therapeutics, a developer of transformative therapies for chronic inflammation and autoimmune diseases, secured $161 million in Series B financing. The round was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities, and Norwest Venture Partners, with participation from new investors such as B Capital. The funds will support the clinical advancement of NVG-2089, a novel immunomodulator designed to reduce autoimmune dysregulation without causing immunosuppression.Non-invasive Blood Glucose Monitoring Device Developer Liom Secures $25 Million in Series A FundingOn December 6, Liom, a developer of non-invasive blood glucose monitoring devices, secured $25 million in Series A funding. The funds will be used to develop and test the device, with the goal of a pre-launch by early 2026. The device utilizes the company's proprietary light- and artificial intelligence-based technology to provide additional health metrics such as heart rate and movement, enabling consumers to adopt an active and healthy lifestyle, improve their habits, and reduce the risk of developing diseases.DNA Data Storage Service Provider Biomory Secures $18 Million in Series A FundingOn December 10, DNA data storage service provider Biomory secured $18 million in Series A funding, led by Crédit Mutuel Innovation, with participation from new investors Blast, Paris Business Angels, and Sorbonne Venture. The company plans to use the funds to advance the development of data center storage devices that can be integrated into server racks.Drug Delivery Platform Developer Qnovia Secures $16 Million in Series B FundingOn December 10, drug delivery platform developer Qnovia secured $16 million in Series B financing, led by Blue Ledge Capital, Evolution VC Partners, Vice Ventures, and Gaingels. Qnovia is a pharmaceutical company focused on developing and commercializing proprietary inhalation device technology to improve patient outcomes. The company's drug delivery platform, RespiRx™, is the first orientation-independent portable vibrating mesh nebulizer, capable of operating effectively in any position held by the patient.Innovative Medical Product Developer EOSVISION Secures Nearly RMB100 Million in Series A FinancingOn December 6, EOSVISION, an innovative medical product developer, secured nearly RMB 100 million in its Series A round of financing, led by Daotong Investment. The proceeds will be used to accelerate the research and development, clinical trials, international development, registration, and marketing expansion of its ophthalmology and regenerative medicine innovation pipeline, including products such as artificial biomimetic cornea, implantable contact lenses, artificial corneal endothelial patches, and artificial dermis.XinHong Life, a developer of ultrasonic energy technology and pharmaceutical-device combination technology, secures tens of millions in Pre-A+ fundingOn December 9, Xinhong Life, a developer of ultrasonic energy technology and pharmaceutical-device combination technology, secured tens of millions in Pre-A+ funding, exclusively led by Mingxi Capital. This round of financing will accelerate the industrialization and commercialization of the company's products, as well as the subsequent development of integrated interventional ultrasound diagnosis and treatment products.AI Physiotherapy Robot Developer De Yi Medical Secures Tens of Millions in Series A FinancingOn December 6, De Yi Medical, a developer of AI physiotherapy robots, secured tens of millions in Series A funding led by Ningbo Keli Sensing Technology Co., Ltd., with participation from Times Prudent and the State-owned Assets Supervision and Administration Commission of Jiangbei District, Ningbo. The proceeds will primarily be used for innovative product development, market expansion, and talent team building, helping the company achieve higher-quality rapid growth.Nansu Technology, a developer of digital therapeutics for pan-brain dysfunction, secures tens of millions of yuan in A+ round financingOn December 6, Nansu Technology, a developer of digital therapeutics for generalized brain dysfunction, secured tens of millions of yuan in an A+ round of financing led by Zhongxi Fund, with participation from Fangtian Education and Zhenghe Xiang. The proceeds will mainly be used for the research and development, regulatory approval, and market promotion of new products.Digital PCR Instrument and RUO Kit Developer, Ruixun Biotech, Secures Tens of Millions in C2 Round FinancingOn December 9, Rayx Biotech, a developer of digital PCR instruments and RUO test kits, secured tens of millions of yuan in a Series C2 round led by RJ HealthCare. The proceeds will be used for clinical registration of digital PCR products both domestically and internationally, market promotion in Europe, and the development of new products, providing strong support for Rayx Biotech to maintain its leading position in the digital PCR and mRNA LNP fields.02 Digital Health Industry DynamicsGSK Collaborates with Relation, a Drug Discovery Technology Service Provider, to Develop New Drugs for Fibrotic Diseases and OsteoarthritisGSK Partners with Drug Discovery Technology Provider Relation on Two Collaborations to Develop New Medicines for Fibrotic Diseases and Osteoarthritis; Relation to Receive up to Over $500 Million, Leveraging its Platform to Discover Novel Disease Targets, Reduce Clinical Failure Risks, and Support GSK’s Global Development and Commercialization.03 Global Digital Health M&A OverviewNVIDIA Acquires Vietnamese AI Healthcare Company VinbrainOn December 10, NVIDIA acquired VinBrain, a Vietnamese AI healthcare company. VinBrain is a healthcare company centered on artificial intelligence. They integrate AI into medical and medical imaging diagnostics. The company's flagship product is DrAid, an AI-based doctor assistant that provides automated chest X-ray diagnosis and screening for radiologists.Siemens Healthineers Acquires Novartis Molecular Imaging BusinessOn December 10, Siemens Healthineers completed the acquisition of Novartis' Advanced Accelerator Applications (AAA) molecular imaging business. Novartis' AAA molecular imaging business, located in Europe, produces and sells radiopharmaceuticals used for positron emission tomography (PET). Following the completion of the acquisition, AAA will become a subsidiary of Siemens Healthineers. This acquisition strengthens Siemens Healthineers' PETNET Solutions network. The transaction includes AAA Molecular Imaging's manufacturing and distribution network, approximately 420 employees, an established product portfolio, and partnerships with radioligand imaging developers.ArteryNet/Arterial Orange Industry Think Tank/China Renaissance/BGI Co-Win/Rock Health/Mobile Health News/Fierce Health, etc.
Compiled by: Liu Shuxia
